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Interventions
The two regimens of generic drugs were based on the World Health Organization (WHO)'s list of essential drugs to treat and prevent cardiovascular disease. The background comparator was no treatment.
The primary prevention regimen was given to patients without a history of cardiovascular disease and consisted of aspirin, a statin, an angiotensin-converting enzyme inhibitor, and a calcium-channel blocker. The doses were 81mg aspirin, 40mg lovastatin, 10mg lisinopril, and 5mg amlodipine. Patients at four different 10-year absolute risks of cardiovascular disease (5%, 15%, 25%, and 35%) and those older than 55 years with or without any additional risk factor were considered.
The secondary prevention regimen was given to patients with a history of cardiovascular disease and consisted of aspirin, a statin, an angiotensin-converting enzyme inhibitor, and a beta-blocker. The doses were the same, except that metoprolol was substituted for amlodipine.
Location/setting
The six low-and middle-income regions, defined by the World Bank (East Asia and Pacific, Eastern Europe and central Asia, Latin America and Caribbean, Middle East and north Africa, South Asia, and sub-Saharan Africa)/primary care.
Methods

Analytical approach:
The analysis was based on a Markov model, with a lifetime horizon. The authors stated that a societal perspective was adopted.
Effectiveness data:
The clinical data were from a selection of relevant sources, which included high-quality studies, such as published metaanalyses for primary prevention and clinical trials for secondary prevention. The details of these sources were presented in an online appendix. The disease progression was based on Framingham equations. The key input for the model was the relative-risk reduction in cardiovascular disease-related events (death, ischaemic heart disease, and stroke), with the
